Abeona Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial – Rare Disease Report
Rare Disease Report |
Abeona Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial
Rare Disease Report The ongoing Phase 1/2 trial for ABO-102 (AAV-SGSH) by the clinical-stage biopharmaceutical company is a first-in-man clinical trial utilizing a single intravenous injection of AAV gene therapy for MPS IIIA patients. Abeona, focused on developing novel … |
